SER-262: Phase Ib started

Seres began a 24-week, double-blind, placebo-controlled, dose-escalation, U.S. Phase Ib trial to evaluate 104-108 spore colony forming units (SCFUs) of oral SER-262 in about 60 patients who have exper...